A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3
Clinical trial NCT00002106 · COMPLETED
Trial details
- NCT number
- NCT00002106
- Sponsor
- Glaxo Wellcome
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Enrollment
- 104
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.